Products ({{ products.totalElements }})
News & articles ({{ wpNewsAndArticles.total_posts }})
Blog entries ({{ wpBlogEntries.total_posts }})

{{ String(product.attributes.name) }} {{ String(product.attributes.productType) }} - NEW	{{ String(product.attributes.artNo) }}	{{ (String(product.attributes.sizeStr) != 'undefined') ? String(product.attributes.sizeStr) : '–' }}	Not available On Request {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} Login for price

Full search results →

No products found

News {{ news.date \| formatDate }} #{{tag.name}}

No news & articles found

Full search results →

blog entry {{ blogEntry.date \| formatDate }}

No blog entries found

Full search results →

Anti-Hu CD19 PE-DyLight® 594

Antibodies Primary

Make a customized order

Article No

AFC-5DBHOO-100

Application

Species Reactivity

human

Size

100 tests

Clone

LT19

Source / Host

mouse

Article No

AFC-5DBHOO-100

Application

Species Reactivity

human

Size

100 tests

Clone

LT19

Source / Host

mouse

Specifications
Suggested protocols
References

Specifications

Application	FC
Article No	AFC-5DBHOO-100
Biosite Brand	Biosite Flow
Country Availability	all
Clone	LT19
Clone Type	monoclonal
Conjugation	PE/DyLight 594
Description	Anti-Hu CD19 PE-DyLight® 594
Recommended Dilution	The purified antibody is conjugated with tandem dye PE-DyLight™ 594 (PE-DL594) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Supplier	Nordic Biosite
Entrez Gene ID	930
Format	PE-DyLight<sup>®</sup> 594
Immunogen	Daudi human Burkitt lymphoma cell line
Isotype	IgG1
Keywords	CD and Related Antigens (Human)
Notes	CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
Alias Names	B4, Leu-12, CVID3
Previous Article No	AFC-5607-2
Product Type	Antibodies Primary
Protocol	Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Purification	Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-DyLight®594 (PE-DyLight®594) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Research area	Immunology
Size	100 tests
Source / Host	mouse
Species Reactivity	human
Storage	Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Substrate / Buffer	Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Technical Specifications	The antibody LT19 reacts with an extracellular epitope of CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.
UniProt Number	P15391
Product Page Updated	2024-01-03T12:18:20.318Z

Suggested protocols

Flow Cytometry

References

*Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106(10):3567-74. Epub 2005 Jul 26., URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16046525&query_hl=14&itool=pubmed_DocSum ,*Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2013 Sep 13. doi: 10.1111/ijlh.12149., URL: http://www.ncbi.nlm.nih.gov/pubmed/24028768 ,*Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014 Jul;153(1):49-55., URL: http://www.ncbi.nlm.nih.gov/pubmed/24709112 ,*Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171(7):3697-704. , URL: https://www.ncbi.nlm.nih.gov/pubmed/14500668?dopt=,*Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan;58(1):138-45., URL: https://pubmed.ncbi.nlm.nih.gov/18835928/,,*Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56(9):3057-69., URL: https://pubmed.ncbi.nlm.nih.gov/17763445/,*van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354(18):1901-12., URL: https://pubmed.ncbi.nlm.nih.gov/16672701/,*Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99(2):584-9., URL: https://pubmed.ncbi.nlm.nih.gov/11781242/,*Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162(12):7088-94., URL: https://pubmed.ncbi.nlm.nih.gov/10358152/,,

Shipping info

The delivery time for this item is approximately 8-16 business days. Read more